Vanguard Personalized Indexing Management’s Dyne Therapeutics DYN Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Buy	+9,429	New	+$175K	﹤0.01%	1901

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Personalized Indexing Management's DYN Position: Q2 2026 in Review

Vanguard Personalized Indexing Management opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 9,429 shares worth $209K. The stake represents ﹤0.01% of the portfolio and ranks #1901 among its holdings.

246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Vanguard Personalized Indexing Management held 9,429 shares of Dyne Therapeutics worth $209K as of Q2 2026.
Dyne Therapeutics was a new Vanguard Personalized Indexing Management position in Q2 2026.
Dyne Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #1901 holding.
246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.